Tuesday April 21, 2015   
Find us Facebook Follow us on Twitter Watch us on YouTube    
Donate Now
Research Grants

Carboplatin Phase I Clinical Trials
Led by J. Bradley Elder, MD at the Department of Neurological Surgery at the Ohio State University Medical Center

Despite surgery, chemotherapy, and radiation, malignant brain tumors are almost uniformly fatal. The use of carboplatin to treat brain tumors has been limited by its toxicity and its poor ability to get out of the blood and into the brain and the tumor (blood-brain barrier). Directly administering the carboplatin into the brain will eliminate its toxicity and increase the amount getting into the tumor.

Recent studies have been carried out by Dr. Barth and his research team at Ohio State University and his collaborator, Dr. Elleaume and her team in Grenoble, France. They have demonstrated that direct delivery of carboplatin into the brain tumor, either alone or in combination with radiation therapy (RT), produced the best survival data ever obtained with a rat brain tumor that has been incurable by almost all other types of treatment. Significantly increased survival times and cures were observed compared to animals treated with Temozolomide and RT. Direct delivery of the carboplatin to the brain yielded high drug concentrations in the tumor, undetectable amounts outside the brain, with no neurotoxicity. This could be a very promising approach to treat patients with recurrent brain tumors.

This clinical trial will evaluate the toxicity and safety of carboplatin delivered directly into the brain, in patients with recurrent brain tumors. Patients enrolled have had primary therapy including surgery, radiation and Temozolomide, and tumor recurrence that necessitates a second operation to remove tumor. During surgery, infusion catheters will be placed into the brain tissue surrounding the resection cavity. Carboplatin subsequently will be infused for 72 hours. Over the next 12 months, patients will be evaluated for toxicity, radiographic tumor response, time to progression and mean survival. The proposed Phase I clinical trial represents a new and innovative approach to treat patients with recurrent brain tumors.

Click here for a full list of research grants funded by Voices Against Brain Cancer.



Voices Against Brain Cancer is a not-for-profit public charity recognized by the IRS under 501 (c) (3)